Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Psychopharmacology May 16, 2008 Karsten Heekeren, Jörg Daumann, Anna Neukirch et al. 158 citations
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states. Previous studies reported a significant reduction of MMN after ketamine (N-methyl-D-aspartate acid [NMDA] antagonist model) but not after psilocybin (5HT2A agonist model). OBJECTIVES: The...